Rozman T A, Klövekorn G, Kompa H
Z Hautkr. 1984 Dec 1;59(23):1623-34.
Ten institutions participated in a controlled clinical trial in order to evaluate the efficacy of topical meclocycline and erythromycin in comparison to placebo with regard to papulopustular acne. Both drugs had been incorporated in the same galenic formulation that served as placebo. The vehicle employed in this study guaranteed equally favorable drug relies for both preparations. At the end of the trial, 419 patients could be evaluated for efficacy. As impartial criterion for evaluation, the number of inflammatory lesions on the right side of the face was counted before and after three months of treatment. In addition, we recorded the patients' and physicians' overall judgment at the end of the study. As compared with placebo, meclocycline as well as erythromycin brought about statistically significant improvement already after two months of treatment. After three months, the results were statistically very highly significant (p less than 0.001). At any time of the study, there could not be demonstrated any difference between the two groups treated with meclocycline and erythromycin.
十家机构参与了一项对照临床试验，以评估局部应用甲氯环素和红霉素与安慰剂相比治疗丘疹脓疱型痤疮的疗效。两种药物均被制成与安慰剂相同的剂型。本研究中使用的赋形剂确保了两种制剂的药物依赖情况同样良好。试验结束时，419名患者可进行疗效评估。作为公正的评估标准，在治疗三个月前后对右侧面部的炎性皮损数量进行计数。此外，我们在研究结束时记录了患者和医生的总体判断。与安慰剂相比，甲氯环素和红霉素在治疗两个月后就已带来具有统计学意义的改善。三个月后，结果具有统计学高度显著性（p小于0.001）。在研究的任何时候，接受甲氯环素和红霉素治疗的两组之间均未显示出任何差异。
